Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Neuroscience ; 123(3): 743-9, 2004.
Article in English | MEDLINE | ID: mdl-14706786

ABSTRACT

Exposure to 70% N(2)O evokes a robust antinociceptive effect in C57BL/6 (B6) but not in DBA/2 (D2) inbred mice. This study was conducted to identify quantitative trait loci (QTL) in the mouse genome that might determine responsiveness to N(2)O. Offspring from the F(2) generation bred from B6 and D2 progenitors exhibited a broad range of responsiveness to N(2)O antinociception as determined by the acetic acid-induced abdominal constriction test. QTL analysis was then used to dissect this continuous trait distribution into component loci, and to map them to broad chromosomal regions. To this end, 24 spleens were collected from each of the following four groups: male and female F(2) mice responding to 70% N(2)O in oxygen with 100% response (high-responders); and male and female F(2) mice responding with 0% response (low-responders). Genomic DNA was extracted from the spleens and genotyped with simple sequence length polymorphism MapPairs markers. Findings were combined with findings from the earlier QTL analysis from BXD recombinant inbred mice [Brain Res 725 (1996) 23]. Combined results revealed two significant QTL that influence responsiveness to nitrous oxide on proximal chromosome 2 and distal chromosome 5, and one suggestive QTL on midchromosome 18. The chromosome 2 QTL was evident only in males. A significant interaction was found between a locus on chromosome 6 and another on chromosome 13 with a substantial effect on N(2)O antinociception.


Subject(s)
Chromosome Mapping/methods , Nitrous Oxide/pharmacology , Pain Measurement/drug effects , Quantitative Trait Loci/drug effects , Quantitative Trait Loci/genetics , Animals , Female , Genotype , Male , Mice , Mice, Inbred C57BL , Mice, Inbred DBA , Pain Measurement/methods
2.
J Biomed Sci ; 7(4): 299-303, 2000.
Article in English | MEDLINE | ID: mdl-10895052

ABSTRACT

Previously it was demonstrated that nitrous oxide antinociception in the mouse abdominal constriction test is mediated by kappa-opioid receptors. Since nitrous oxide is thought to cause the neuronal release of endogenous opioid peptide to stimulate opioid receptors, this study was designed to identify the opioid peptides involved, especially in the spinal cord, by determining whether nitrous oxide antinociception can be differentially inhibited by intrathecally (i. t.) administered antisera to different opioid peptides. Male NIH Swiss mice were pretreated i.t. with rabbit antisera to opioid peptides then exposed 24 h later to one of three different concentrations of nitrous oxide in oxygen. Dose-response curves constructed from the data indicated that the antinociceptive effect of nitrous oxide was significantly antagonized by antisera to various dynorphins (DYNs) and methionine-enkephalin (ME), but not by antiserum to beta-endorphin (beta-EP). The AD(50) values for nitrous oxide antinociception were significantly elevated by antisera to DYNs and ME but not beta-EP. These findings of this study support the hypothesis that nitrous oxide antinociception in the mouse abdominal constriction test involves the neuronal release of DYN and ME in the spinal cord.


Subject(s)
Analgesics, Non-Narcotic/antagonists & inhibitors , Immune Sera/immunology , Immune Sera/pharmacology , Nitrous Oxide/antagonists & inhibitors , Opioid Peptides/antagonists & inhibitors , Opioid Peptides/immunology , Analgesics, Non-Narcotic/pharmacology , Analgesics, Opioid/antagonists & inhibitors , Analgesics, Opioid/immunology , Analgesics, Opioid/metabolism , Animals , Dose-Response Relationship, Drug , Dynorphins/antagonists & inhibitors , Dynorphins/immunology , Dynorphins/metabolism , Enkephalin, Methionine/antagonists & inhibitors , Enkephalin, Methionine/immunology , Enkephalin, Methionine/metabolism , Immune Sera/administration & dosage , Injections, Spinal , Male , Mice , Nitrous Oxide/pharmacology , Opioid Peptides/metabolism , Pain/metabolism , Pain/physiopathology , Pain Measurement , Peptide Fragments/antagonists & inhibitors , Peptide Fragments/immunology , Peptide Fragments/metabolism , Spinal Cord/drug effects , Spinal Cord/metabolism , Spinal Cord/physiopathology , beta-Endorphin/antagonists & inhibitors , beta-Endorphin/immunology , beta-Endorphin/metabolism
3.
Brain Res ; 675(1-2): 190-4, 1995 Mar 27.
Article in English | MEDLINE | ID: mdl-7796128

ABSTRACT

Previous work has suggested that the antinociceptive effect of nitrous oxide (N2O) in rats is mediated, at least in part, by beta-endorphin (beta-EP) and that centrally administered beta-EP stimulates release of methionine-enkephalin (ME) in the rat spinal cord. Since inhibition of central nitric oxide (NO) production has been found to suppress N2O antinociception, we examined the possible involvement of NO in the release of spinal cord ME by i.c.v. beta-EP. Urethane-anesthetized, male Sprague-Dawley rats were intrathecally (i.t.) perfused with artificial cerebrospinal fluid (aCSF) and fractions of perfusate were assayed for immunoreactive (i.r.) ME. The beta-EP-induced increase in ME concentration in the i.t. perfusate was significantly suppressed by perfusing the animal with aCSF containing 100 microM L-NG-nitro arginine (L-NOARG), an inhibitor of NO synthase (NOS). The further addition of 50 microM L-arginine (L-ARG), but not D-arginine (D-ARG), to the aCSF reversed the suppression of the ME change by L-NOARG. However, the potency of L-ARG decreased with increasing concentrations of L-ARG. On the other hand, increasing the concentration of L-NOARG in the aCSF to 250 microM failed to produce a greater suppression of the beta-EP-induced increase in ME. These findings suggest that NO may mediate the beta-EP-induced release of ME in the spinal cord and that interference with this mechanism might be an explanation for the antagonism of N2O antinociception in rats by NOS inhibitors.


Subject(s)
Enkephalin, Methionine/metabolism , Neurons/metabolism , Nitric Oxide/physiology , beta-Endorphin/pharmacology , Animals , Arginine/analogs & derivatives , Arginine/pharmacology , Injections, Intraventricular , Injections, Spinal , Male , Neurons/drug effects , Nitric Oxide/antagonists & inhibitors , Nitroarginine , Radioimmunoassay , Rats , Rats, Sprague-Dawley , Spinal Cord/drug effects , Spinal Cord/metabolism , beta-Endorphin/administration & dosage
4.
J Pharmacol Exp Ther ; 269(2): 601-8, 1994 May.
Article in English | MEDLINE | ID: mdl-8182526

ABSTRACT

Administration of the anesthetic gas N2O evoked an antinociceptive effect in two rodent antinociception paradigms. In the mouse abdominal constriction test, pretreatment with the nitric oxide synthase (NOS) inhibitor L-NG-nitroarginine (L-NOARG) caused dose-related antagonism of the antinociceptive effect of N2O but not of either morphine or trans(+/-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl] benzeneacetamide methane sulfonate. This antinociceptive effect was also antagonized by systemic pretreatment with the NOS inhibitors L-NG-nitroarginine methyl ester (L-NAME) and L-NG-monomethylnitroarginine. The antagonism of N2O by L-NOARG and L-NAME was completely reversed by i.c.v. administration of L-arginine but not D-arginine. In the absence of NOS inhibition, N2O antinociception was potentiated by i.c.v. treatment with L-arginine but not D-arginine. The i.c.v. pretreatment with L-NAME also reduced N2O antinociception; this antagonism was also stereospecifically reversed by L-arginine. In the rat hot plate test, the antinociceptive response to 70% N2O was antagonized in dose-related manner by i.c.v. pretreatment with L-NOARG or L-NAME. N2O antinociception was restored by i.c.v. treatment with L-arginine but not D-arginine. However, neither L-arginine nor D-arginine alone affected N2O antinociception. These results implicate a key role for NO in the mediation of the antinociceptive effects of N2O in both mice and rats.


Subject(s)
Analgesics/antagonists & inhibitors , Nitric Oxide/biosynthesis , Nitrous Oxide/antagonists & inhibitors , 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer , Animals , Arginine/administration & dosage , Arginine/analogs & derivatives , Arginine/pharmacology , Cerebral Ventricles/drug effects , Cerebral Ventricles/metabolism , Male , Mice , Morphine/pharmacology , NG-Nitroarginine Methyl Ester , Nitric Oxide/antagonists & inhibitors , Nitric Oxide/metabolism , Pyrrolidines/pharmacology , Rats , Rats, Sprague-Dawley , omega-N-Methylarginine
SELECTION OF CITATIONS
SEARCH DETAIL
...